• Je něco špatně v tomto záznamu ?

Barriers in inflammatory bowel disease care in Central and Eastern Europe: a region-specific analysis

M. Prokopič, G. Gilca-Blanariux, P. Lietava, A. Trifan, A. Pietrzak, A. Ladic, M. Brinar, S. Turcan, T. Molnár, P. Bánovčin, M. Lukáš

. 2023 ; 16 (-) : 17562848231174290. [pub] 20230612

Status neindexováno Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc23009547

Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are chronic immune-mediated diseases with a high incidence and prevalence in Europe. Since these are diseases with associated disability, they require complex management and the availability of high-quality healthcare resources. We focused on the analysis of IBD care in selected countries of Central and Eastern Europe (Croatia, the Czech Republic, Hungary, Moldova, Poland, Romania and Slovakia) targeting the availability and reimbursement of diagnostic and therapeutic modalities, the role of IBD centers and also education and research in IBD. As part of the analysis, we created a questionnaire of 73 statements organized in three topics: (1) diagnostics, follow-up and screening, (2) medications and (3) IBD centers. The questionnaire was filled out by co-authoring IBD experts from individual countries, and then the answers and comments on the questionnaire were analyzed. We identified that despite the financial burden, which still partially persists in the region, the availability of some of the cost-saving tools (calprotectin test, therapeutic drug monitoring) differs among countries, mainly due to variable reimbursement from country to country. In most participating countries, there also remains a lack of dedicated dietary and psychological counseling, which is often replaced by recommendations offered by gastroenterologists. However, there is adequate availability of most of the currently recommended diagnostic methods and therapies in each participating country, as well as the implementation of established IBD centers in the region.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23009547
003      
CZ-PrNML
005      
20230721095543.0
007      
ta
008      
230707s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1177/17562848231174290 $2 doi
035    __
$a (PubMed)37333465
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Prokopič, Michal $u Department of Gastroenterology, Jessenius Faculty of Medicine, Comenius University Bratislava, Kollárova 2, Martin 036 01, Slovakia $1 https://orcid.org/0000000300393759
245    10
$a Barriers in inflammatory bowel disease care in Central and Eastern Europe: a region-specific analysis / $c M. Prokopič, G. Gilca-Blanariux, P. Lietava, A. Trifan, A. Pietrzak, A. Ladic, M. Brinar, S. Turcan, T. Molnár, P. Bánovčin, M. Lukáš
520    9_
$a Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are chronic immune-mediated diseases with a high incidence and prevalence in Europe. Since these are diseases with associated disability, they require complex management and the availability of high-quality healthcare resources. We focused on the analysis of IBD care in selected countries of Central and Eastern Europe (Croatia, the Czech Republic, Hungary, Moldova, Poland, Romania and Slovakia) targeting the availability and reimbursement of diagnostic and therapeutic modalities, the role of IBD centers and also education and research in IBD. As part of the analysis, we created a questionnaire of 73 statements organized in three topics: (1) diagnostics, follow-up and screening, (2) medications and (3) IBD centers. The questionnaire was filled out by co-authoring IBD experts from individual countries, and then the answers and comments on the questionnaire were analyzed. We identified that despite the financial burden, which still partially persists in the region, the availability of some of the cost-saving tools (calprotectin test, therapeutic drug monitoring) differs among countries, mainly due to variable reimbursement from country to country. In most participating countries, there also remains a lack of dedicated dietary and psychological counseling, which is often replaced by recommendations offered by gastroenterologists. However, there is adequate availability of most of the currently recommended diagnostic methods and therapies in each participating country, as well as the implementation of established IBD centers in the region.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Gilca-Blanariux, Georgiana $u Department of Gastroenterology, Grigore T Popa University of Medicine and Pharmacy, Iasi, Romania $u Sf Spiridon County Clinical Emergency Hospital, Iasi, Romania
700    1_
$a Lietava, Peter $u Department of Gastroenterology, Jessenius Faculty of Medicine, Comenius University Bratislava, Martin, Slovakia
700    1_
$a Trifan, Anca $u Department of Gastroenterology, Grigore T Popa University of Medicine and Pharmacy, Iasi, Romania $u Sf Spiridon County Clinical Emergency Hospital, Iasi, Romania
700    1_
$a Pietrzak, Anna $u Second Gastroenterology Department, Centre of Postgraduate Medical Education, Warsaw, Poland
700    1_
$a Ladic, Agata $u Department of Gastroenterology and Hepatology, Division of Internal Medicine, University Hospital Center Zagreb, Zagreb, Croatia
700    1_
$a Brinar, Marko $u Department of Gastroenterology and Hepatology, Division of Internal Medicine, University Hospital Center Zagreb, Zagreb, Croatia
700    1_
$a Turcan, Svetlana $u Department of Gastroenterology, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Moldova
700    1_
$a Molnár, Tamás $u First Department of Medicine, University of Szeged Faculty of Medicine, Szeged, Hungary
700    1_
$a Bánovčin, Peter $u Department of Gastroenterology, Jessenius Faculty of Medicine, Comenius University Bratislava, Martin, Slovakia
700    1_
$a Lukáš, Milan $u IBD Clinical and Research Center, ISCARE a.s. and the First Faculty of Medicine, Charles University, Prague, Czech Republic
773    0_
$w MED00177174 $t Therapeutic advances in gastroenterology $x 1756-283X $g Roč. 16, č. - (2023), s. 17562848231174290
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37333465 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230707 $b ABA008
991    __
$a 20230721095536 $b ABA008
999    __
$a ok $b bmc $g 1958407 $s 1195811
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 16 $c - $d 17562848231174290 $e 20230612 $i 1756-283X $m Therapeutic advances in gastroenterology $n Therap Adv Gastroenterol $x MED00177174
LZP    __
$a Pubmed-20230707

Najít záznam

Citační ukazatele

Možnosti archivace